Gilead tested an antibody many times. Āshibio salvages it, with $40M and...
Gilead had tested a humanized antibody called andecaliximab, or GS-5745, in close to 1,000 patients before giving up on it a few years ago. The company had multiple mid- and late-stage attempts in...
View ArticleAphaia targets prediabetes with oral glucose drug
The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis. The company is developing an oral glucose treatment targeting...
View ArticleForbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure
Plus, news about Cinclus Pharma, Biophytis and Blanver: Forbion’s new fund: The Dutch VC firm’s BioEconomy Fund I closed €75 million (about $80 million) to invest in sustainable startups across food,...
View ArticleClik here to view.
Silence’s siRNA candidate for cardiovascular disease continues to deliver in...
Silence Therapeutics has unveiled additional data from a mid-stage trial of its siRNA therapy candidate in certain people at risk of heart episodes, setting the stage for potential registrational...
View ArticleFDA makes it easier for biosimilars to obtain interchangeability designations
The FDA on Thursday began easing the process for biosimilar developers to demonstrate interchangeability with their brand-name biologics. The agency previously required studies to prove that switching...
View ArticleClik here to view.
PTC touts Phase 2 biomarker data for Huntington’s drug, showing...
PTC Therapeutics presented new biomarker data for a Huntington’s disease drug Thursday morning that it says demonstrates evidence of reducing the mutant huntingtin protein (mHTT) in patients’ systems,...
View ArticleClik here to view.
Jazz's stock dips after mid-stage fail in essential tremor
Jazz Pharmaceuticals said Thursday that the highest dose of suvecaltamide failed a Phase 2b trial in essential tremor, a neurological condition that causes involuntary shaking. Patients who took a 30...
View ArticleClik here to view.
Corrected: Emergent sells Baltimore facility for $30M
Emergent BioSolutions is selling off a Baltimore manufacturing site for $30 million to Bora Pharmaceuticals. Joe Papa “The decision to sell our Camden manufacturing facility is aligned with our...
View ArticleAnother fire breaks out at a Novo Nordisk site; Thermo Fisher earmarks $58M...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. A fire broke out at a Novo Nordisk office building in Bagsværd,...
View ArticleClik here to view.
Takeda budgets $230M for plasma therapy facility expansion in California
As a part of Takeda’s larger plan to boost production of its plasma-derived therapies, the company is allocating $230 million to expand its manufacturing site in Los Angeles. Giles Platford The site...
View ArticleCBER chief floats rare disease hub to better communicate across centers
SAN DIEGO – The FDA’s biologics center director Peter Marks said the agency is considering the creation of a rare disease hub to better combine the expertise of both its drug and biologics experts....
View ArticleFDA to pharma companies: Using CRO Synapse's studies 'unacceptable'
The FDA is not holding punches against India-based CRO Synapse, saying that studies conducted by the group are “unacceptable” due to data integrity issues and should not be used by pharma sponsors. The...
View ArticleZealand Pharma hits early efficacy goal for amylin weight loss candidate
Zealand Pharma’s amylin analogue weight loss candidate petrelintide helped patients lose a mean 8.6% of their body weight in a Phase 1b trial, meeting executives’ early goals and setting the stage for...
View ArticleScientists just discovered a new genetic clue for delaying Alzheimer’s...
Research on one of the most famous families in neurology has shed new light on the interplay between Alzheimer’s disease and a rare gene that protects against it, as well as how that learning might one...
View ArticleClik here to view.
Gilead's twice-a-year injection fully prevented HIV in Phase 3 study with...
There were no cases of HIV in over 2,000 cisgender women who received a twice-a-year preventive HIV injection developed by Gilead as part of a Phase 3 clinical trial. The data, announced Thursday...
View ArticleTectonic enters public markets in one of few biotech reverse mergers this year
Tectonic Therapeutic, a biotech from renowned entrepreneur and researcher Tim Springer, completed its reverse merger with gene therapy company Avrobio on Thursday and will begin trading as $TECX on...
View ArticleFDA widens Sarepta’s Duchenne gene therapy label to older boys in significant...
The FDA has broadened the label for Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy to patients ages 4 and older. The approval goes beyond the patient population in which the company...
View ArticleClik here to view.
Moncef Slaoui joins board at mRNA biotech; Gamida Cell retools with ex-Amryt...
Moncef Slaoui → Moncef Slaoui has reemerged this week with another board appointment, making his way to mRNA drug developer Arcturus Therapeutics. Endpoints News scooped you last September on Slaoui’s...
View ArticleUS, EU pledge $2B+ to help boost vaccine manufacturing in Africa
Eyes were on Paris with the official launch of the African Vaccine Manufacturing Accelerator (AVMA) on Thursday. The EU is contributing €750 million to the accelerator, while the US is pledging $1.58...
View ArticleObesity care startup knownwell buys an AI weight loss platform
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more startups get into the business of treating obesity, one weight loss startup acquired another to...
View Article